Olaparib | search
Click here to view Olaparib news from 60+ newspapers.
Bookmark or Share- FDA approves olaparib for adjuvant treatment of high-risk early breastOn March 11, 2022, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected...
- Olaparib (Lynparza) | Cancer information | Cancer Research UKHow does olaparib work? Olaparib is a targeted drug called a PARP inhibitor. PARP is a protein that helps damaged cells to repair themselves. Olaparib stops PARP working. Some cancer cells rely on PARP to keep their DNA healthy. This includes cancer cells with a change in the BRCA genes.
- Olaparib - WikipediaOlaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
- LYNPARZA® (olaparib) - Official Patient WebsiteLYNPARZA is a prescription medicine used to treat adults who have: advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene.
- Olaparib: Uses, Dosage, Side Effects, Warnings - Drugs.comOlaparib (Lynparza) is a PARP inhibitor used to treat types of breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, fallopian tube cancer, or peritoneal cancer. Olaparib works by blocking a protein called PARP which helps cancer cells repair themselves, blocking PARP causes the cancer cells die.
More
